RIGL - Rigel Pharmaceuticals Inc. (RIGL) Q1 2024 Earnings Call Transcript
2024-05-07 21:46:15 ET
Rigel Pharmaceuticals, Inc. (RIGL)
Q1 2024 Earnings Conference Call
May 7, 2024 4:30 PM ET
Company Participants
Ray Furey - Executive Vice President, General Counsel and Corporate Secretary
Raul Rodriguez - President and Chief Executive Officer
Dave Santos - Chief Commercial Officer
Lisa Rojkjaer - Chief Medical Officer
Dean Schorno - Chief Financial Officer
Conference Call Participants
Yigal Nochomovitz - Citigroup
Kristen Kluska - Cantor Fitzgerald
Farzin Haque - Jefferies
Presentation
Operator
Greetings and welcome to Rigel Pharmaceuticals Financial Conference Call for the First Quarter 2024. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce our first speaker, Ray Furey, Rigel’s Executive Vice President, General Counsel and Corporate Secretary. Thank you, Mr. Furey. You may now begin.
Ray Furey
Thank you. Welcome to our first quarter 2024 financial results and business update conference call. The financial press release for the first quarter 2024 was issued a short while ago and can be viewed along with the slides for this presentation in the News & Events section of our Investor Relations site on rigel.com.
As a reminder, during today’s call, we may make forward-looking statements regarding our financial outlook and our plans and timing for regulatory product development. These statements are subject to risks and uncertainty that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31st, 2023 and subsequent filings with the SEC, including our Quarter 1 quarterly report on Form 10-Q on file with the SEC.
Any forward-looking statements are made only as of today’s date and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances.
At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?...
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2024 Earnings Call Transcript